Genistein abolishes the increased cyclooxygenase-2 (COX-2) to 5-FU resistant HT-29 colon cancer cells (207) and induces the cleavage of Bid to TRAIL resistant human hepatoma cells (208), exerting its sensitizing effects. Here, PTGS2 is linked to malignant colon neoplasm.